1. Medtech Insight
  2. >>Archive

PEOPLE - UK private equity and venture capital firm 3I makes appointment:

As part of its aim to increase its investment in healthcare, London-based UK private equity and venture capital firm 3i has appointed Peter Chambre as an industrialist-in-residence. Mr Chambre has 13 years' experience of leading healthcare companies, including Bespak (CEO), the Cambridge Antibody Technology Group (CEO) and Celera Genomics Group (COO). As part of 3i's industrialist-in-residence programme, Mr Chambre will identify, evaluate and complete deals in the healthcare sector, and provide significant levels of leadership assistance to businesses that are backed by 3i. Mr Chambre is currently a non-executive director of BTG (life sciences, UK) and Spectris (precision engineering, UK).

As part of its aim to increase its investment in healthcare, London-based UK private equity and venture capital firm 3i has appointed Peter Chambre as an industrialist-in-residence. Mr Chambre has 13 years' experience of leading healthcare companies, including Bespak (CEO), the Cambridge Antibody Technology Group (CEO) and Celera Genomics Group (COO). As part of 3i's industrialist-in-residence programme, Mr Chambre will identify, evaluate and complete deals in the healthcare sector, and provide significant levels of leadership assistance to businesses that are backed by 3i. Mr Chambre is currently a non-executive director of BTG (life sciences, UK) and Spectris (precision engineering, UK).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

State And International Enforcement Agencies May Step Up Amid Uncertain Federal Environment

 
• By Elizabeth Orr

States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.

Execs On The Move: 21-25 April 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.